Anise Oil

Summary

Anise Oil (CHEMBL2108976) is a phase-3 clinical-stage unknown; indicated across 3 conditions including irritable bowel syndrome and inborn error of immunity.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108976
Name	Anise Oil
Type	Unknown
Max phase	3

Also known as: Ae-anise seed, Anise, Anise burnet saxifrage seed, Anise burnet saxifrage whole, Anise fruit, Anise oil, Anise seed, Anise seed powder, Anise volatile oil, Aniseed, Anisi aetheroleum, Anisi fructus

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555
inborn error of immunity	2	MONDO:0003778	HP:0002721
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).